Max-Delbruck-Centrum Fur Molekulare Medizin

Max-Delbruck-Centrum Fur Molekulare Medizin in Der Helmholtz-Gemeinschaft

Max-delbr&uuml;ck-Centrum F&uuml;r Molekulare Medizin

Charité-Universitaets-Medezin Berlin

Charité – Universitätsmedizin Berlin

Ulrike Stein

Wolfgang Walther

Peter Michael Schlag

Ulrike Sack

Christian Lange

Dominic Scudiero

Holger Schwabe

Robert Shoemaker

A method for inhibiting, reducing and/or reducing the risk of cancer metastasis in a subject, including identifying a subject as in need of inhibiting, reducing and/or reducing the risk of cancer metastasis, by identifying the subject as having a cancer with an elevated or up-regulated level of S100A4 transcription compared to a level in non-oncogenic cells, and administering to the subject a therapeutically effective amount of niclosamide or a niclosamide derivate, thereby inhibiting or reducing S100A4 transcription, so as to inhibit, reduce and/or reduce the risk of cancer metastasis, wherein 15 to 400 mg niclosamide or niclosamide derivate is administered per kg body weight of the subject (mg/kg), 1 or 2 times daily.

Niclosamide for the treatment of cancer metastasis

The present invention refers to the nucleic acid sequence encoding for the polypeptide of 7a5/Prognostin and to its uses, in particular for the tumour diagnostics and tumour therapy of metastasising tumours.

7a5/prognostin and use thereof for the diagnostic and therapy of tumors

Embodiments of the invention relate to a vector system that allows one to induce expression of therapeutically relevant genes in mammalian cells. Such a vector system may be useful for medicine and in the pharmaceutical industry. A vector comprises base structures suitable for expression in mammalian cells as well as either the whole of or parts of the gene promoter of human Major Vault Protein (MVP), also known as LRP (Lung Resistance Protein) as well as a gene encoding a therapeutic protein or non-translated RNA. As the MVP promoter is inducible by therapy (for example, but not limited to, chemotherapy or hyperthermia), the vector system provides combinations of therapeutic methods with gene therapy in a controlled fashion, resulting in more efficient treatment of tumor diseases.

Use of the human LRP/MVP promotor for a vector that can be induced by therapy

The invention concerns a cytotoxic, MDR-associated substance for producing a therapeutic agent for tumor therapy, which is characterized by a) the tumor cells of a tumor patient are chemosensitized with a cytokine, b) the scope of expression of one or more MDR-associate genes (e.g. mdrl, Mrp, Lrp) in the tumor tissues of the patient is determined according to the beginning of the cytokine treatment, c) the time domain is determined, in which the expression of one or more MDR-associate genes is substantially reduced by the cytokine treatment, d) the patient is treated in the determined time domain (&ldquo;therapeutic window&rdquo;) with a therapeutically effective amount of a cytotoxic, MDR-associated substance, the effectiveness of which is influenced (enhanced) by the expression of one or more MDR-associate genes. The use of said substance leads to an improved tumor therapy.

Process for treating tumors with cytotoxic substances

Growing community of inventors

Schwanebeck, Germany

Ulrike Stein